Compare Neurocrine Biosciences Inc (NBIX) vs Spotify Technology (SPOT) Price & Performance

Neurocrine Biosciences IncTrade

Spotify TechnologyTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Spotify Technology — how do they compare? Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B), while Spotify Technology trades at $496.6 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 6.3× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.

	NBIX	SPOT
Market Cap	$16.46B	$103.00B
Sector	Health	Media
52-Week High	$185.50	$738.53
52-Week Low	$123.10	$412.75
Enterprise Value	$16.48B	$92.70B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Spotify Technology

Spotify (SPOT) trades at $511.82, up 4.85% with a bullish technical outlook. The company reported strong Q2 2026 results with revenue growth and record gross margins, though earnings missed estimates due to higher AI and marketing costs. Analyst consensus is bullish with a $598.20 price target, supported by 61.5% buy ratings. Recent news highlights Spotify's initiative to label AI-generated artists, enhancing platform transparency.

The outlook remains positive with robust subscriber growth and monetization efforts, but risks include competitive pressures and cost management. Upside potential exists if execution continues, while misses on user growth or margin targets could weigh on the stock. The current valuation reflects optimism for sustained profitability.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 4 hours agoBullish View details →

SPOT

Spotify to label AI-generated music accounts and exclude them from recommendationsNew York Post · 1 day agoNeutral Spotify labels AI-generated artists with 'AI Persona' tags, excluding them from recommendations.TechCrunch · 1 day agoNeutral View details →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

About Spotify Technology

Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.